A health claim petition requesting the FDA allow use of eight dietary supplement health claims associating chromium picolinate supplementation with reduced risk of insulin resistance, type 2 diabetes and related disease conditions has been submitted. Nutrition 21 holds patents for the therapeutic use of chromium picolinate in addressing insulin resistance and type 2 diabetes.

The FDA has accepted the health claim filing as complete and has initiated the review process. Proposed health claims include that chromium picolinate may reduce: insulin resistance; risk of abnormally elevated blood sugar levels; risk of cardiovascular disease when caused by abnormally elevated blood sugar levels; risk of type 2 diabetes and risk of retinopathy when caused by abnormally high blood sugar levels (among others). Nutrition 21, Stacey Antine, 914-701-4567, www.nutrition21.com